Loading data for KYMR — first visit, this takes a few seconds.

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM: KYMR · Real-Time Price · USD

117.39

+0.11 (0.09%)

At close: Sep 04, 2026, 8:00 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	75.27
Market Cap	9.66B
Revenue (ttm)	105M
Net Income (ttm)	-300M
	1.97
	-3.25
	n/a
	-23.7
P/B (ttm)	6.44
P/S (ttm)	92.96
Earnings Date	Nov 3, 2026

Ask	133.99
Volume	378,568
Avg. Volume (20D)	850,496
Open	112.77
Previous Close	117.28
Day's Range	112.77 - 118.28
52-Week Range	42.22 - 130.05
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 21, 2020

Employees 273

Stock Exchange NasdaqGM

Ticker Symbol KYMR

Website https://www.kymeratx.com

Full Company Profile

Financial Performance

In 2025, Kymera Therapeutics's revenue was 39.21M, a decrease of -16.7% compared to the previous year's 47.07M. Earnings were -311.35M, an increase of 39.08%.

Financial Statements

Earnings Surprise

Kymera Therapeutics has released their quarterly earnings on Aug 5, 2026:

Revenue of $65M misses estimates by $0, with 466.40% YoY growth.
EPS of -0.62 exceeds estimates by 0.12, with 34.74% YoY growth.

Next Earnings Release

Kymera Therapeutics, Inc. is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · Motley Fool

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Enrollment completed six months early; $1.5B cash runway into 2029.

4 weeks ago · MT Newswires

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after a

1 month ago · Zacks

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

1 month ago · Simply Wall St.

Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)

Kymera Therapeutics, Inc. has reported past second-quarter 2026 results showing a reduced net loss of US$61.21 million and lower basic and diluted loss per share of US$0.62, while also completing Phas...

1 month ago · Moby

Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Kymera Therapeutics, Inc.'s Q2 2026 earnings call

Page 1 of 2

Kymera Therapeutics, Inc. (KYMR)